摘要
Hepatocellular carcinoma(HCC)is the second leadingcause of cancer-related death worldwide.At firstdiagnosis,HCC is multifocal in about 35-40%of patients(1,2).According to Western guidelines,the treatmentof multifocal(non-metastatic)HCC is well codified:transplantation is indicated for HCCs within Milan criteria(2-3 nodules≤30 mm),ablation for non-transplantableHCCs within Milan criteria,and chemoembolizationfor the remaining patients(3).
